Verzenio and tamoxifen – pro
VErzenio and tamoxifen was studied in a clinical trial: A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (Next MONARCH 1), NCT02747004. It was published in 202, showing that the addition of tamoxifen to abemaciclib (Verzenio) resulted in an improvement in overall survival (OS) compared with abemaciclib monotherapy in patients with hormone receptor (HR)positive, HER2-negative metastatic breast cancer, with benefit observed across all patient subgroups, according to results from the final OS analysis of the next monarch trial presented during the 2020 ESMO Virtual Congress.
Hamilton E. nextMONARCH : Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancer. Virtual 2020 ESMO Congress; September 19-21, 2020; virtual. Accessed September 19, 2020. Abstract 273O.
Rugo, HS. Achieving improved survival outcomes in advanced breast cancer. N Engl J Med. 2019;381(4):371-372. doi:10.1056/NEJMe1906236
Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2 metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218-5224. Doi: 10.1158/1078-0432.CCR-17-0754